Jessa hospital
Hasselt, 3500, Belgium
NCT Number: NCT04877808
The aim of this study is to assess the incidence of bacterial surinfections (sepsis, VAP and catheter infections) in COVID-19 patients admitted to the ICU from 13th of March 2020 until 17h of October 2020. In addition, the association of these infections with the dose of corticosteroids, the length of stay in ICU and in hospital, the presence of venous thromboembolism, the number of bacterial episodes, the different types of bacteria causing the infections and ICU mortality will be evaluated as well as the associations between the presences of thrombi and bacteremia/catheter sepsis.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Hasselt, 3500, Belgium
Approximately 5% of patients with respiratory impairment develop a severe form with acute respiratory failure and require specialized management in the Intensive Care Unit (ICU). Invasive mechanical ventilation (IVM) exposes ICU patients to a particular risk of a nosocomial infectious complication called ventilator-associated pneumonia (VAP). In Europe, the incidence density is 18.3 VAP per 1000 days of IMV.
The coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) emerged in December 2019 and has rapidly spread worldwide (Liu). The mortality of critical ill patients with COVID-19 has been reported variously as low as 11% and as high as 61% (Liu). Since March 2020, several thousand people have been receiving IMV due to severe COVID-19.
Informal exchanges between clinicians regarding the current pandemic indicate a high frequency of VAP. Several factors may account for a higher incidence of VAP in the population hospitalized in the ICU for SARS CoV-2 infection (Blonz 2021):
Aim The aim of this study is to assess the incidence of bacterial surinfections (sepsis, VAP and catheter infections) in COVID-19 patients admitted to the ICU from 13th of March 2020 until 17h of October 2020. In addition, the association of these infections with the dose of corticosteroids, the length of stay in ICU and in hospital, the presence of venous thromboembolism, the number of bacterial episodes, the different types of bacteria causing the infections and ICU mortality will be evaluated as well as the associations between the presences of thrombi and bacteremia/catheter sepsis.
Design This is a retrospective, single-center study investigating the incidence of bacterial surinfections in COVID-19 patients admitted to the ICU from 13th of March 2020 until 17th of October 2020.
Inclusion criteria
All adult COVID-19 patients admitted to the ICU from 13th of March until 17th of October 2020 were included.
Outcome measures The primary endpoint of this retrospective study is to assess the incidence of bacterial surinfections (sepsis, VAP and catheter infections) in COVID-19 patients admitted to the ICU from 13th of March 2020 until 17th of October 2020.
Secondary endpoints are the association of these infections with the dose of corticosteroids, the length of stay in ICU and in hospital, the presence of venous thromboembolism, the number of bacterial episodes, the different types of bacteria causing the infections and ICU mortality as well as the associations between the presences of thrombi and bacteremia/catheter sepsis in COVID-19 patients admitted to the ICU between 13th of March 2020 until 17th of October 2020.
Additional data collection
Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: through study completion, 8 months
Incidence of bacterial surinfections (sepsis) in COVID-19 patients admitted to the ICU
Time frame: through study completion, 8 months
Incidence of bacterial surinfections (VAP) in COVID-19 patients admitted to the ICU
Time frame: through study completion, 8 months
Incidence of bacterial surinfections (catheter infections) in COVID-19 patients admitted to the ICU
Time frame: through study completion, 8 months
Correlation of bacterial surinfections with the dose of cortisosteroids
Time frame: through study completion, 8 months
Correlation of bacterial surinfections with the length of stay in ICU and hospital
Time frame: through study completion, 8 months
Correlation of bacterial surinfections with the presence of venous thromboembolism
Time frame: through study completion, 8 months
Correlation of bacterial surinfections with the number of bacterial episodes
Time frame: through study completion, 8 months
Correlation with the different types of bacteria
Time frame: through study completion, 8 months
Correlation of bacterial surinfections with the ICU mortality
Time frame: through study completion, 8 months
Correlation between presences of thrombi and bacteremia/catheter sepsis
Jessa Hospital
Other
Incidence and Predictive Value of Bacterial Surinfections on In-hospital Mortality in COVID-19 ICU Patients: a Longitudinal Single-center Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04747249
COVID-19, Coronaviridae Infections
Caen, France
View Trial DetailsNCT04924881
COVID-19, Coronaviridae Infections
Shatin, Hong Kong
View Trial DetailsNCT04939506
Behavior, COVID-19
New Orleans, Louisiana, United States
View Trial DetailsNCT04705116
COVID-19, Coronaviridae Infections
Los Angeles, California, United States
View Trial Details